Richter Heralds Xarelto Opportunity As Proof Generics Still Have Life
However, Recent Roll-Out Of Rivaroxaban Hamstrung By Bayer’s Legal Efforts
Hungarian leader Gedeon Richter spoke at length of its recent European roll-out of generic competition to Bayer’s Xarelto blockbuster, while also providing key updates for its biosimilar pipeline, as the firm reported financial first-half results.
